C

CTC Bio Inc
KOSDAQ:060590

Watchlist Manager
CTC Bio Inc
KOSDAQ:060590
Watchlist
Price: 4 440 KRW -2.52% Market Closed
Market Cap: 107.4B KRW
Section:
 

Relative Value

The Relative Value of one CTC Bio Inc stock under the Base Case scenario is hidden KRW. Compared to the current market price of 4 440 KRW, CTC Bio Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTC Bio Inc Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
98
vs Industry
66
Median 3Y
1.3
Median 5Y
1.3
Industry
2.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
16
Median 3Y
-32.8
Median 5Y
-28.9
Industry
21.4
More Details
11.8
P/OCF
P/OCF
Price to OCF
11.8
vs History
77
vs Industry
6
Median 3Y
19.8
Median 5Y
20
Industry
16.4
More Details
33.8
P/FCFE
P/FCFE
Price to FCFE
33.8
vs History
25
vs Industry
1
Median 3Y
12.2
Median 5Y
-11.7
Industry
22.8
More Details
1.5
P/B
P/B
Price to Book Value
1.5
vs History
98
vs Industry
31
Median 3Y
2.4
Median 5Y
2.3
Industry
2.2
More Details
0.9
EV/S
EV/S
Enterprise Value to Sales
0.9
vs History
96
vs Industry
65
Median 3Y
1.4
Median 5Y
1.5
Industry
2.9
More Details
2.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.3
vs History
96
vs Industry
50
Median 3Y
4
Median 5Y
4.9
Industry
5.5
More Details
16.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
16.7
vs History
58
vs Industry
0
Median 3Y
22.8
Median 5Y
23.2
Industry
13
More Details
180.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
180.5
vs History
9
vs Industry
24
Median 3Y
-27.1
Median 5Y
-32.6
Industry
16.5
More Details
13.9
EV/OCF
EV/OCF
Enterprise Value to OCF
13.9
vs History
73
vs Industry
6
Median 3Y
22.6
Median 5Y
23.2
Industry
15.6
More Details
16.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.4
vs History
66
vs Industry
0
Median 3Y
22.3
Median 5Y
22.9
Industry
18.7
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
96
vs Industry
45
Median 3Y
1.4
Median 5Y
1.4
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
CTC Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
CTC Bio Inc
KOSDAQ:060590
108.9B KRW 0.8 -124.6 16.7 180.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
266.1B CHF 4.3 28.2 12 14
UK
AstraZeneca PLC
LSE:AZN
218.6B GBP 5.1 31.4 108.7 159
CH
Novartis AG
SIX:NOVN
216.6B CHF 4.9 18.9 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.5 10.8 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
KR
C
CTC Bio Inc
KOSDAQ:060590
Average P/E: 24.7
Negative Multiple: -124.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.5
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
C
CTC Bio Inc
KOSDAQ:060590
Average EV/EBITDA: 401.4
16.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
C
CTC Bio Inc
KOSDAQ:060590
Average EV/EBIT: 1 728.7
180.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.